Adjuvant therapy improves recurrence-free survival in HCC patients

Camrelizumab plus apatinib in a real-world setting has shown significant benefits in recurrence-free survival (RFS) for patients with hepatocellular carcinoma (HCC) with microvascular invasion following radical resection. The comparison between adjuvant therapy (99 patients) and observation (172 patients) indicated a hazard ratio of 0.52 for RFS improvement (p<0.001). However, overall survival did not significantly differ (hazard ratio 0.62; p=0.079). Grade 3 or 4 treatment-related adverse events occurred in 20.7% of treated patients.